Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 2/20 | 0.35 |
| ▸ | BRAF | P15056 | 2/20 | 0.35 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29780227 | 1.00 | METAP2 (0.38) | METAP2CYP1A2GRM5RAF1BRAF | |
| SCHEMBL23462206 | 0.83 | IDO1 (0.44) | METAP2CYP1A2GRM5RAF1BRAF | |
| SCHEMBL29780223 | 0.83 | IDO1 (0.44) | METAP2CYP1A2GRM5RAF1BRAF | |
| SCHEMBL29780205 | 0.73 | IDH1 (0.37) | METAP2CYP1A2GRM5CSNK2A1IDH1 | |
| SCHEMBL23461094 | 0.73 | IDH1 (0.37) | METAP2CYP1A2GRM5CSNK2A1IDH1 | |
| SCHEMBL23461171 | 0.72 | MKNK1 (0.62) | — | |
| SCHEMBL29780211 | 0.72 | MKNK1 (0.62) | — | |
| SCHEMBL23461602 | 0.72 | EPAS1 (0.42) | PTGS1PTGS2 | |
| SCHEMBL29780196 | 0.72 | EPAS1 (0.42) | PTGS1PTGS2 | |
| SCHEMBL23461066 | 0.71 | EPAS1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024438-A1 | INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| CN-114760994-A | Inhibitors of HIF-2 alpha | 艾库斯生物科学有限公司 | 2022-07-15 | — | — | CN | disclosed |
| WO-2021113436-A1 | INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024438-A1 | INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | METAP2 2493/4885CYP1A2 1605/4885GRM5 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.